Navigation Links
EORTC, BIG, and Agendia Announce Completion of Patient Recruitment for International MINDACT Study
Date:10/18/2011

implifies complex treatment decisions for their physicians. Agendia's Symphony™ suite of breast cancer products is based on the analysis of hundreds of genes in a patient's breast and provides unprecedented biological insight to address complex treatment decisions. Symphony™ includes MammaPrint®, the first and only FDA-cleared IVDMIA breast cancer recurrence assay, as well as BluePrint®, a molecular subtyping assay, TargetPrint®, an ER/PR/HER2 expression assay, and TheraPrint®, a therapy selection assay. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo or hormonal therapy, and which patients do not require these treatments and can instead be treated with other less arduous and costly methods.

In addition to the Symphony™ suite of tests, Agendia has a rich pipeline of genomic products in development based on its world-class genomic platform. The company also collaborates with pharmaceutical companies to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and MINDACT trials.

Agendia was founded in 2003 as a spin-off of the Netherlands Cancer Institute and is based in Amsterdam, the Netherlands, and Irvine, California, United States.

For more information about Agendia please visit:  http://www.agendia.com.


'/>"/>
SOURCE Agendia B.V.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Agendia Successfully Completes Bi-Annual FDA Inspection
2. Agendia Presents Broad Array of Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO 2010 Annual Meeting
3. Agendia Receives New York State Laboratory Permit and Laboratory Accreditation by College of American Pathologists
4. Medicare Administrator Establishes Reimbursement Coding Policy for Agendias Breast Cancer Recurrence Test MammaPrint(R)
5. Agendia Raises US $23 Million in Series E Financing
6. Agendia Supports Genentechs Citizens Petition Urging FDA to Hold In-Vitro Diagnostic Tests to One Set of Scientific and Regulatory Standards
7. Agendia Opens CLIA-Registered U.S. Genomics Laboratory
8. Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting
9. Agendia to Present at BioCenturys Future Leaders in the Biotech Industry Conference
10. Agendia Presents Data Supporting MammaPrints Predictive and Prognostic Power at 2009 St. Gallen Breast Cancer Conference
11. Agendia Appoints Seasoned Diagnostics Executive Albert A. Luderer to Supervisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... Calif. (PRWEB) , ... July 02, 2015 , ... Sleepless ... improve an individual’s quality of sleep, launched its Indiegogo campaign on June 23. Sound ... Luzi's voice command technology makes it effortless to use, while the integration of the ...
(Date:7/1/2015)... PARIS , July 1, 2015 ... key developer of biotech crops, today announce a ... generations of insect control traits. "Growers ... the realities of advancing insect resistance. We are ... insect control technology with Genective,s capability in developing ...
(Date:7/1/2015)... India , July 1, 2015  Strand Life ... generation sequencing technology to empower cancer care, today announced ... chief executive officer. In his expanded role as now ... strategy, business expansion and worldwide operations effective immediately.  Dr. ... chairman and CEO since its founding in 2000, will ...
(Date:7/1/2015)... CHANDLER, Ariz. , July 1, 2015 ... announced it has earned three Gold, three Silver, and ... Business Awards gala held in Chicago ... recognized as the premier business awards program in the ... and recognizes our company,s strength in developing leaders, cultivating ...
Breaking Biology Technology:Luzi Smart Lamp Recently Launched Indiegogo Campaign 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 3AgBiome and Genective collaborate to create novel insect-resistant crops 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3
... Agendia BV, a,world leader in the rapidly evolving field ... Officer Laura van ,t Veer has,received a prestigious 2007 ... Cancer Research Foundation. The Pink Ribbon ,Breast Cancer ... breast cancer researchers with a total value of,32 M$. ...
... Oximetry Unit, NEW YORK, Oct. 22 SPO ... biosensor and microprocessor,technologies for use in portable monitoring devices, ... unit. This sales milestone has,been achieved within three years ... The bulk of the 100,000 units sold include the ...
... Holdings Asia and,its co-investors today announced that they ... the world,s largest privately held,crop- protection and life-science ... billion (US$2.2 billion). The sale will culminate a,five-year ... private,equity firm with investment teams in Japan, Greater ...
Cached Biology Technology:Agendia BV Announces That its Chief Research Officer Laura van 't Veer has Received a 2007 Breast Cancer Research Foundation Award 2SPO Medical Announces Major Sales Milestone 2SPO Medical Announces Major Sales Milestone 3Olympus Capital Announces Agreement to Sell Arysta LifeScience Corporation 2Olympus Capital Announces Agreement to Sell Arysta LifeScience Corporation 3
(Date:6/18/2015)... , June 18, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market announces that ... featured segment on "Money on the Mark", scheduled to air ... June 20 th . The ... be from 7:00 to 8:00pm EST. NXT-ID, Inc.,s CEO ...
(Date:6/17/2015)... SAN JOSE, Calif. , June 17, 2015 ... leader in human interface solutions, today announced that ... has adopted the Synaptics ® ClearPad ® ... family of display driver integrated circuits (DDICs) for ... Note Pro. By leveraging ClearPad for full in-cell ...
(Date:6/16/2015)... 16, 2015  With the increasing number and severity ... top concern. The recent compromise of Federal employee ... strong authentication within government agencies. HYPR Corp. ... password (OTP) authenticator, has been submitted for testing and ... 3 validation for tamper proofing. The ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3
... in which the aging process is linked to DNA damage--which ... influences--and the various ways in which cells repair that damage. ... fruit flies make use of a different mix of molecular ... are reported by William Engels and colleagues at the University ...
... “vile and cynical exploitation?by the alternative medicines industry, argues a ... that up to 80% of all patients with cancer take ... treat their cancer, writes Jonathan Waxman, Professor of Oncology at ... use of many of these approaches is obtuse ?one might ...
... The widely used breast cancer drug tamoxifen (Nolvadex®), which ... full strength indefinitely if used along with a second ... investigators from the National Cancer Institute (NCI), part of ... results appear in the December 11, 2006, issue of ...
Cached Biology News:Age-related changes in DNA repair illuminate the connection between age and genetic damage 2Protect patients from exploitation by alternative medicines industry 2Restoring tamoxifen sensitivity in resistant breast cancer cells 2